Crescent Biopharma, Inc.
Status: Publicly traded
Direct answer
Crescent Biopharma, Inc. is publicly traded on NASDAQ under the ticker CBIO.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance...
Can you invest in Crescent Biopharma, Inc.?
Yes. Crescent Biopharma, Inc. trades publicly on NASDAQ as CBIO.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Crescent Biopharma, Inc.
Detailed equity research is provided by MarketSnap.